OCUL
HEALTHCAREOcular Therapeutix Inc
$9.71+0.00 (+0.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OCUL Today?
No stock-specific AI insight has been generated for OCUL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.23$16.44
$9.71
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-1.44
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume3.8M
Avg Volume (10D)—
Shares Outstanding219.0M
OCUL News
20 articles- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 8, 2026
- Ocular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation DivergeYahoo Finance·May 7, 2026
- Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile ReturnsYahoo Finance·May 6, 2026
- Ocular Therapeutix Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 EarningsYahoo Finance·May 5, 2026
- Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 5, 2026
- Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To ExpectYahoo Finance·May 4, 2026
- How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 TrialYahoo Finance·May 1, 2026
- How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL)Yahoo Finance·Apr 30, 2026
- Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial DataYahoo Finance·Apr 29, 2026
- Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMDYahoo Finance·Apr 29, 2026
- Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026Yahoo Finance·Apr 28, 2026
- Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 DataMarketbeat·Apr 28, 2026
- Ocular Therapeutix™ to Participate in May Scientific and Investor ConferencesYahoo Finance·Apr 27, 2026
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026Yahoo Finance·Apr 22, 2026
- Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLIYahoo Finance·Apr 20, 2026
- Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices?Yahoo Finance·Apr 13, 2026
- Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMDYahoo Finance·Apr 13, 2026
- Assessing Whether Ocular Therapeutix (OCUL) Looks Undervalued After Recent Mixed Share Price PerformanceYahoo Finance·Apr 12, 2026
All 20 articles loaded
Price Data
Open$9.37
Previous Close$9.71
Day High$9.84
Day Low$9.35
52 Week High$16.44
52 Week Low$6.23
52-Week Range
$6.23$16.44
$9.71
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-1.44
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume3.8M
Avg Volume (10D)—
Shares Outstanding219.0M
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—